104 related articles for article (PubMed ID: 28233047)
1. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Marshall WL; Feng HP; Caro L; Talaty J; Guo Z; Huang X; Panebianco D; Ma J; Mangin E; O'Reilly TE; Butterton JR; Yeh WW
Eur J Clin Pharmacol; 2017 May; 73(5):593-600. PubMed ID: 28233047
[TBL] [Abstract][Full Text] [Related]
2. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Barbour A; Reitmann C; Jumes P; Gilmartin J; Wolford D; Valesky R; Martinho M; Butterton JR; Iwamoto M; Fraser I; Webster L; Yeh WW
Clin Transl Sci; 2018 Nov; 11(6):562-572. PubMed ID: 30040871
[TBL] [Abstract][Full Text] [Related]
3. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Sabo JP; Lang B; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
[TBL] [Abstract][Full Text] [Related]
4. Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
Lin S; Ionescu A; Maynard-Scott J; Kennedy M; Walling DP; Furey M; Singh JB
Clin Transl Sci; 2024 May; 17(5):e13791. PubMed ID: 38700236
[TBL] [Abstract][Full Text] [Related]
5. Endogenous thrombin potential changes during the first cycle of oral contraceptive use.
Westhoff CL; Pike MC; Cremers S; Eisenberger A; Thomassen S; Rosing J
Contraception; 2017 May; 95(5):456-463. PubMed ID: 28088496
[TBL] [Abstract][Full Text] [Related]
6. Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study.
Mercier AK; Kois AK; Karsanji D; Baldry R; Birve F; Hedwall M; Molodetskyi O; Gillen M
Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38686600
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
[TBL] [Abstract][Full Text] [Related]
8. Repeated exposure to physiologically effective doses of contraceptive hormones ethinyl estradiol or levonorgestrel do not alter the reinforcing effects of a brief visual stimulus in ovary-intact rats.
McNealy KR; Oevermann MW; Knabel ML; Fitzwater A; Gipson CD; Barrett ST; Bevins RA
Horm Behav; 2024 May; 161():105506. PubMed ID: 38387104
[TBL] [Abstract][Full Text] [Related]
9. Weight and body composition changes during oral contraceptive use in obese and normal weight women.
Mayeda ER; Torgal AH; Westhoff CL
J Womens Health (Larchmt); 2014 Jan; 23(1):38-43. PubMed ID: 24156617
[TBL] [Abstract][Full Text] [Related]
10. Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage.
Ji B; Zhou F; Han L; Yang J; Fan H; Li S; Li J; Zhang X; Wang X; Chen X; Xu Y
Transl Stroke Res; 2017 Aug; 8(4):334-340. PubMed ID: 28243834
[TBL] [Abstract][Full Text] [Related]
11. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Hézode C; Colombo M; Bourlière M; Spengler U; Ben-Ari Z; Strasser SI; Lee WM; Morgan L; Qiu J; Hwang P; Robertson M; Nguyen BY; Barr E; Wahl J; Haber B; Chase R; Talwani R; Marco VD;
Hepatology; 2017 Sep; 66(3):736-745. PubMed ID: 28256747
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
Belperio PS; Shahoumian TA; Mole LA; Backus LI
Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.
Morales AL; Liriano-Ward L; Tierney A; Sang M; Lalos A; Hassan M; Nair V; Schiano T; Satoskar R; Smith C
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28239909
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Forns X; Berenguer M; Herzer K; Sterneck M; Donato MF; Andreone P; Fagiuoli S; Cieciura T; Durlik M; Calleja JL; Mariño Z; Shukla U; Verbinnen T; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; Janssen K; Kalmeijer R; Jessner W
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28295849
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
17. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Lacombe K; Fontaine H; Dhiver C; Metivier S; Rosenthal E; Antonini T; Valantin MA; Miailhes P; Harent S; Batisse D; Pageaux GP; Chas J; Aumaitre H; Dominguez S; Allegre T; Lafeuillade A; Billaud E; De Truchis P; Perre P; Leroy V; De Ledinghen V; Sogni P; Dabis F; Zhao Y; Filipovics A; Fedchuk L; Akremi R; Bennai Y; Salmon Ceron D
J Acquir Immune Defic Syndr; 2017 May; 75(1):97-107. PubMed ID: 28272163
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Ponziani FR; Siciliano M; Lionetti R; Pasquazzi C; Gianserra L; D'Offizi G; Gasbarrini A; Pompili M
Am J Kidney Dis; 2017 Aug; 70(2):297-300. PubMed ID: 28258770
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics of Dasabuvir.
King JR; Zha J; Khatri A; Dutta S; Menon RM
Clin Pharmacokinet; 2017 Oct; 56(10):1115-1124. PubMed ID: 28258380
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics of Paritaprevir.
Menon RM; Polepally AR; Khatri A; Awni WM; Dutta S
Clin Pharmacokinet; 2017 Oct; 56(10):1125-1137. PubMed ID: 28236252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
